IL160533A0 - Methods of screening molecules that are used to prevent cardiovascular diseases - Google Patents
Methods of screening molecules that are used to prevent cardiovascular diseasesInfo
- Publication number
- IL160533A0 IL160533A0 IL16053302A IL16053302A IL160533A0 IL 160533 A0 IL160533 A0 IL 160533A0 IL 16053302 A IL16053302 A IL 16053302A IL 16053302 A IL16053302 A IL 16053302A IL 160533 A0 IL160533 A0 IL 160533A0
- Authority
- IL
- Israel
- Prior art keywords
- methods
- cardiovascular diseases
- concentration
- reducing
- relates
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000030169 Apolipoprotein C-III Human genes 0.000 abstract 1
- 108010056301 Apolipoprotein C-III Proteins 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 abstract 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 108010073614 apolipoprotein A-IV Proteins 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000004141 reverse cholesterol transport Effects 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0111598A FR2829581A1 (fr) | 2001-09-07 | 2001-09-07 | Methodes de criblage de molecules utiles pour la prevention ou le traitement du syndrome metabolique, des maladies cardiovasculaires et de l'atherosclerose |
| PCT/FR2002/003040 WO2003023407A1 (fr) | 2001-09-07 | 2002-09-06 | Methodes de criblage de molecules utiles pour la prevention des maladies cardiovasculaires |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL160533A0 true IL160533A0 (en) | 2004-07-25 |
Family
ID=8867065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16053302A IL160533A0 (en) | 2001-09-07 | 2002-09-06 | Methods of screening molecules that are used to prevent cardiovascular diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040198656A1 (de) |
| EP (1) | EP1423707B1 (de) |
| JP (1) | JP2005502883A (de) |
| AT (1) | ATE377760T1 (de) |
| CA (1) | CA2459945A1 (de) |
| DE (1) | DE60223390D1 (de) |
| FR (1) | FR2829581A1 (de) |
| IL (1) | IL160533A0 (de) |
| WO (1) | WO2003023407A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2604333A1 (en) * | 2005-04-15 | 2006-10-19 | Cenix Bioscience Gmbh | Human marker genes and agents for cardiovascular disorders and artherosclerosis |
| US7972802B2 (en) * | 2005-10-31 | 2011-07-05 | University Of Washington | Lipoprotein-associated markers for cardiovascular disease |
| JP5373322B2 (ja) * | 2007-06-05 | 2013-12-18 | 株式会社バイオマーカーサイエンス | 動脈硬化改善・予防効果の評価方法、物質のスクリーニング方法、並びに、マーカーとしての使用 |
| WO2009148050A1 (ja) * | 2008-06-04 | 2009-12-10 | 株式会社バイオマーカーサイエンス | 動脈硬化改善・予防効果の評価方法及び評価用キット、並びに、物質のスクリーニング方法 |
| US8241861B1 (en) | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
| WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
| CN110506056A (zh) | 2017-04-21 | 2019-11-26 | 斯塔滕生物技术有限公司 | 抗apoc3抗体和其使用方法 |
| PE20210119A1 (es) | 2017-10-31 | 2021-01-19 | Staten Biotechnology B V | Anticuerpos anti-apoc3 y metodos de uso de estos |
| AU2019207737B2 (en) | 2018-01-10 | 2023-07-13 | Brightseed, Inc. | Method for modulating metabolism |
| KR102892573B1 (ko) | 2019-07-29 | 2025-12-01 | 브라이트씨드, 인크. | 소화기 건강의 개선 방법 |
| JP2023501483A (ja) | 2019-11-11 | 2023-01-18 | ブライトシード・インコーポレイテッド | 抽出物、消費可能な製品及び抽出物における生物活性代謝産物を濃縮するための方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
| EP0976824A1 (de) * | 1998-07-10 | 2000-02-02 | Amsterdam Molecular Therapeutics | An der Leberregenration beteiligtes Gen und Protein |
| EP1144444A3 (de) * | 1998-12-22 | 2002-01-02 | Genset | Kodierende nuleinsäuren für proteine mit signalsequenzen |
| US20030032783A1 (en) * | 1998-12-22 | 2003-02-13 | Frances Yen-Potin | Apolipoprotein A-IV-related protein: polypeptide, polynucleotide sequences and biallelic markers thereof |
| WO2001000661A2 (en) * | 1999-06-25 | 2001-01-04 | Genset | Carnitine carrier related protein-1 |
| EP1276754A4 (de) * | 2000-04-14 | 2005-04-06 | Nuvelo Inc | Materialien und verfahren betreffend den lipidmetabolismus |
-
2001
- 2001-09-07 FR FR0111598A patent/FR2829581A1/fr not_active Withdrawn
-
2002
- 2002-09-06 EP EP02781372A patent/EP1423707B1/de not_active Expired - Lifetime
- 2002-09-06 WO PCT/FR2002/003040 patent/WO2003023407A1/fr not_active Ceased
- 2002-09-06 DE DE60223390T patent/DE60223390D1/de not_active Expired - Lifetime
- 2002-09-06 IL IL16053302A patent/IL160533A0/xx unknown
- 2002-09-06 US US10/487,334 patent/US20040198656A1/en not_active Abandoned
- 2002-09-06 AT AT02781372T patent/ATE377760T1/de not_active IP Right Cessation
- 2002-09-06 CA CA002459945A patent/CA2459945A1/fr not_active Abandoned
- 2002-09-06 JP JP2003527427A patent/JP2005502883A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2459945A1 (fr) | 2003-03-20 |
| DE60223390D1 (de) | 2007-12-20 |
| ATE377760T1 (de) | 2007-11-15 |
| WO2003023407A1 (fr) | 2003-03-20 |
| EP1423707A1 (de) | 2004-06-02 |
| JP2005502883A (ja) | 2005-01-27 |
| US20040198656A1 (en) | 2004-10-07 |
| EP1423707B1 (de) | 2007-11-07 |
| FR2829581A1 (fr) | 2003-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL160533A0 (en) | Methods of screening molecules that are used to prevent cardiovascular diseases | |
| IL188286A0 (en) | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein | |
| WO2004059318A3 (en) | Methods of detecting the inhibition of fibrocyte formation and methods and compositions for enhancing fibrocyte formation | |
| EA200401471A1 (ru) | Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов | |
| NO20075731L (no) | Inhibitorer av mikrosomalt triglyceridtransferprotein og APO-B-sekresjon | |
| EP1155121A4 (de) | Zusammensetzungen und verfahren zur regulierung des serumcholesterins | |
| TW200510452A (en) | Compositions and methods for treating atherosclerosis | |
| DK1427409T3 (da) | Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer | |
| NO20052921L (no) | Fenylsubstituerte piperidinforbindelser for anvendelse som PPAR aktivatorer | |
| WO2008092644A3 (en) | Fviii-independent fix-mutant proteins for hemophilia a treatment | |
| WO2004005481A3 (en) | Methods for identifying modulators of mda-7 mediated apoptosis | |
| Stanley et al. | Amino acids responsible for reduced affinities of vitamin K-dependent propeptides for the carboxylase | |
| BR0309406A (pt) | Composição farmacêutica, processo de preparação, kit e métodos para tratamento de obesidade, utilização de composição e inibidor de lìpases, inibidor de lìpáses e glucomanan ou konjac e utilização dos mesmos e método de tratamento | |
| TW200503747A (en) | Peptide mediators of reverse cholesterol transport for the treatment of hypercholesterolemia | |
| WO2000057871A3 (en) | Methods for identifying agents that inhibit serum aging factors and uses and compositions thereof | |
| AU2002361471A1 (en) | Alternatively spliced circulating tissue factor | |
| Kondo et al. | Relationship between high-density lipoprotein-cholesterol and malondialdehyde-modified low-density lipoprotein concentrations | |
| ATE333887T1 (de) | Verfahren zur behandlung von instabiler angina pectoris | |
| Kasprzak et al. | PON1 status evaluation in patients with chronic arterial occlusion of lower limbs due to atherosclerosis obliterans | |
| Ettelaie et al. | The mechanism of inhibition of factor III (thromboplastin) activity by apolipoprotein B-100: protein-protein interactions | |
| NO20024769D0 (no) | Forbindelser og fremgangsmåter for senking av kolesterolnivåer uten å indusere hypertriglyceridemi | |
| Januszek | Paraoxonase‐1 and Simvastatin Treatment in Patients with Stable Coronary Artery Disease | |
| BRPI0607839A2 (pt) | compostos 1,1,1-triflúor-3-[(benzil)-(pirimidin-2-il)-amino]-propan- 2-ol substituìdos | |
| DE60107516D1 (de) | Verwendung von Pregabalin zur Asthma Behandlung | |
| NO20070141L (no) | Sma molekyler for behandling av hyperkolesterolemi og relaterte sykdommer |